- Tous > Medicine Information and Evidence for Policy > Information and Publications
- Tous > Medicine Access and Rational Use > Antimicrobial Drug Resistance
- Tous > Quality and Safety: Medicines > Safety and Efficacy
- Mots-clés > antimalarial drug resistance
- Mots-clés > Artemisinin based Combination Therapies (ACT)
- Mots-clés > artemisinin resistance
- Mots-clés > efficacy and safety of medicines
- Mots-clés > evidence-based medicine (EBM)
- Mots-clés > malaria treatment policy
- Mots-clés > monitoring and control system
- Mots-clés > oral artemisinin-based monotherapy (oAMT)
(2014; 7 pages)
The emergence and spread of artemisinin resistance calls for intensified efforts to withdraw oral artemisinin-based monotherapy (oAMT) from the markets. Despite substantial progress, oAMTs are still available in many countries.
Intensified action is needed to protect the therapeutic life of artemisininbased combination therapy (ACT), the mainstay of treatment for malaria caused by Plasmodium falciparum. No alternative medicine is ready to enter the market in the next few years to replace ACTs. The loss of this lifesaving class of medicines would have devastating consequences.